Article info
PDFReview
Essential thrombocythaemia and its neurological complications
- Correspondence to Dr M H Farquharson, Department of Haematology, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK; mira.farquharson{at}luht.scot.nhs.uk
Citation
Essential thrombocythaemia and its neurological complications
Publication history
- First published July 20, 2010.
Online issue publication
April 14, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis
- Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis
- Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations
- Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation
- Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings
- Vertebral artery thrombosis: a rare presentation of primary polycythaemia
- Sagittal sinus thrombosis in JAK2-V617F mutation without overt myeloproliferative disorder
- Essential thrombocythemia in a young man treated for myocardial infarction
- Off-pump coronary artery surgery in a patient with essential thrombocythaemia: two life-threatening complications in the same patient
- Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms